(Over)correction of FMR1 deficiency with YAC transgenics: behavioral and physical features

被引:218
作者
Peier, AM
McIlwain, KL
Kenneson, A
Warren, ST
Paylor, R
Nelson, DL
机构
[1] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA
[2] Emory Univ, Sch Med, Dept Chem, Atlanta, GA 30322 USA
[3] Emory Univ, Sch Med, Howard Hughes Med Inst, Atlanta, GA 30322 USA
关键词
D O I
10.1093/hmg/9.8.1145
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Fragile X syndrome is a common cause of mental retardation involving loss of expression of the FMR1 gene. The role of FMR1 remains undetermined but the protein appears to be involved in RNA metabolism. Fmr1 knock-out mice exhibit a phenotype with some similarities to humans, such as macroorchidism and behavioral abnormalities. As a step toward understanding the function of FMR1 and the determination of the potential for therapeutic approaches to fragile X syndrome, yeast artificial chromosome (YAC) transgenic mice were generated in order to determine whether the Fmr1 knockout mouse phenotype could be rescued. Several transgenic lines were generated that carried the entire FMR1 locus with extensive amounts of flanking sequence. We observed that the YAC transgene supported production of the human protein (FMRP) which was present at levels 10 to 15 times that of endogenous protein and was expressed in a cell- and tissue-specific manner. Macroorchidism was absent in knockout mice carrying the YAC transgene indicating functional rescue by the human protein. Given the complex behavioral phenotype in fragile X patients and the mild phenotype previously reported for the Fmr1 knockout mouse, we performed a more thorough evaluation of the Fmr1 knockout phenotype using additional behavioral assays that had not previously been reported for this animal model. The mouse displayed reduced anxiety-related responses with increased exploratory behavior. FMR1 YAC transgenic mice overexpressing the human protein did produce opposing behavioral responses and additional abnormal behaviors were also observed. These findings have significant implications for gene therapy for fragile X syndrome since overexpression of the gene may harbor its own phenotype.
引用
收藏
页码:1145 / 1159
页数:15
相关论文
共 78 条
[1]   NUCLEUS BASALIS MAGNOCELLULARIS AND HIPPOCAMPUS ARE THE MAJOR SITES OF FMR-1 EXPRESSION IN THE HUMAN FETAL BRAIN [J].
ABITBOL, M ;
MENINI, C ;
DELEZOIDE, AL ;
RHYNER, T ;
VEKEMANS, M ;
MALLET, J .
NATURE GENETICS, 1993, 4 (02) :147-153
[2]   HUMAN AND MURINE FMR-1 - ALTERNATIVE SPLICING AND TRANSLATIONAL INITIATION DOWNSTREAM OF THE CGG-REPEAT [J].
ASHLEY, CT ;
SUTCLIFFE, JS ;
KUNST, CB ;
LEINER, HA ;
EICHLER, EE ;
NELSON, DL ;
WARREN, ST .
NATURE GENETICS, 1993, 4 (03) :244-251
[3]   ENHANCED EXPRESSION OF THE MURINE FMR1 GENE DURING GERM-CELL PROLIFERATION SUGGESTS A SPECIAL FUNCTION IN BOTH THE MALE AND THE FEMALE GONAD [J].
BACHNER, D ;
MANCA, A ;
STEINBACH, P ;
WOHRLE, D ;
JUST, W ;
VOGEL, W ;
HAMEISTER, H ;
POUSTKA, A .
HUMAN MOLECULAR GENETICS, 1993, 2 (12) :2043-2050
[4]  
BAKKER CE, 1994, CELL, V78, P23
[5]   Analysis of domains affecting intracellular localization of the FMRP protein [J].
Bardoni, B ;
Sittler, A ;
Shen, Y ;
Mandel, JL .
NEUROBIOLOGY OF DISEASE, 1997, 4 (05) :329-336
[6]   Purified recombinant Fmrp exhibits selective RNA binding as an intrinsic property of the fragile X mental retardation protein [J].
Brown, V ;
Small, K ;
Lakkis, L ;
Feng, Y ;
Gunter, C ;
Wilkinson, KD ;
Warren, ST .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (25) :15521-15527
[7]  
Ceman S, 1999, MOL CELL BIOL, V19, P7925
[8]   Abnormal dendritic spines in fragile X knockout mice: Maturation and pruning deficits [J].
Comery, TA ;
Harris, JB ;
Willems, PJ ;
Oostra, BA ;
Irwin, SA ;
Weiler, IJ ;
Greenough, WT .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (10) :5401-5404
[9]   PRELIMINARY-REPORT OF A SIMPLE ANIMAL BEHAVIOR MODEL FOR THE ANXIOLYTIC EFFECTS OF BENZODIAZEPINES [J].
CRAWLEY, J ;
GOODWIN, FK .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1980, 13 (02) :167-170
[10]  
Crawley J.N., 1989, CURR OPIN PSYCHIATR, V2, P773